NeuClone Reveals Rivals To Opdivo And Keytruda

Australian Biosimilars Specialist Is Developing Nivolumab And Pembrolizumab

 
• By Dave Wallace

Australia’s NeuClone has revealed further details of its pipeline, offering an update that includes a glimpse at two further biosimilar projects that are in active development.

Spotlights
Neuclone has revealed two of its biosimilar candidates • Source: Shutterstock

More from Biosimilars

More from Products